StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)

Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –

Kiniksa Pharmaceuticals International cash

Cash and short-term investments held at the end of each period.

Kiniksa Pharmaceuticals International's cash was $568.76M at Sep 30, 2026. For fiscal 2025 it was $414.07M, up 70.0% from the year before. The highest annual figure on record is $414.07M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$414.07M+70.0%
FY2024Dec 31, 2024$243.63M+18.1%
FY2023Dec 31, 2023$206.37M+8.3%
FY2022Dec 31, 2022$190.61M+4.6%
FY2021Dec 31, 2021$182.20M-43.7%
FY2020Dec 31, 2020$323.48M+38.6%
FY2019Dec 31, 2019$233.38M-24.1%
FY2018Dec 31, 2018$307.30M+573.0%
FY2017Dec 31, 2017$45.66M-18.6%
FY2016Dec 31, 2016$56.08M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$568.76M+61.5%
Q2 FY2026Jun 30, 2026$525.93M+70.9%
Q1 FY2026Mar 31, 2026$468.09M+74.4%
Q4 FY2025Dec 31, 2025$414.07M+70.0%
Q3 FY2025Sep 30, 2025$352.10M+57.3%
Q2 FY2025Jun 30, 2025$307.78M+40.7%
Q1 FY2025Mar 31, 2025$268.34M+25.7%
Q4 FY2024Dec 31, 2024$243.63M+18.1%
Q3 FY2024Sep 30, 2024$223.78M+11.3%
Q2 FY2024Jun 30, 2024$218.76M+18.3%
Q1 FY2024Mar 31, 2024$213.55M+13.9%
Q4 FY2023Dec 31, 2023$206.37M+8.3%
Q3 FY2023Sep 30, 2023$201.08M+0.2%
Q2 FY2023Jun 30, 2023$184.99M+33.9%
Q1 FY2023Mar 31, 2023$187.49M+28.8%
Q4 FY2022Dec 31, 2022$190.61M+4.6%
Q3 FY2022Sep 30, 2022$200.72M+0.3%
Q2 FY2022Jun 30, 2022$138.21M-38.8%
Q1 FY2022Mar 31, 2022$145.58M-44.9%
Q4 FY2021Dec 31, 2021$182.20M-43.7%
Q3 FY2021Sep 30, 2021$200.18M-45.1%
Q2 FY2021Jun 30, 2021$225.87M-10.5%
Q1 FY2021Mar 31, 2021$264.03M+29.3%
Q4 FY2020Dec 31, 2020$323.48M+38.6%
Q3 FY2020Sep 30, 2020$364.40M+40.8%
Q2 FY2020Jun 30, 2020$252.40M-12.2%
Q1 FY2020Mar 31, 2020$204.21M-37.5%
Q4 FY2019Dec 31, 2019$233.38M-24.1%
Q3 FY2019Sep 30, 2019$258.75M-23.4%
Q2 FY2019Jun 30, 2019$287.45M-20.0%
Q1 FY2019Mar 31, 2019$326.53M+47.5%
Q4 FY2018Dec 31, 2018$307.30M+573.0%
Q3 FY2018Sep 30, 2018$337.86M+389.4%
Q2 FY2018Jun 30, 2018$359.19M+348.9%
Q1 FY2018Mar 31, 2018$221.42M+294.9%
Q4 FY2017Dec 31, 2017$45.66M–
Q3 FY2017Sep 30, 2017$69.04M–
Q2 FY2017Jun 30, 2017$80.01M–
Q4 FY2016Dec 31, 2016$56.08M–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?